

Curriculum Vitae

Personal information

First name(s) / Surname(s)	Fabio Nicolini
Address(es)	
Telephone(s)	
E-mail	fabio.nicolini@irst.emr.it
Nationality	Italian
Date of birth	
Gender	M

Occupational field **Oncology Researcher**

Work experience

Dates	09/2017- Present
Occupation or position held	Scientific researcher
Main activities and responsibilities	Identification of novel antibodies with therapeutic properties that can specifically target the cancer cells through analysis of the B lymphocyte repertoire of patients with melanoma or pleural mesothelioma who are responsive to treatment with immunotherapy or vaccination to dendritic cells. PI. Dr. M.Mazza Development of a project coordinated by the Alliance Against Cancer (ACC) network and aimed at increasing the use of CAR-T cell-based immunotherapy in patients with hematologic malignancies and in solid tumors.
Name and address of employer	Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" IRST-IRCCS. Via P. Maroncelli 40, Meldola (FC), Italy.
Type of business or sector	Immunotherapy, Cell Therapy and Biobank (ITCB) Unit.

Education and training

Dates	11/2012 – 06/2017
Title of qualification awarded	Ph.D. in Molecular Biosciences
Principal subjects/occupational skills covered	Role of the Polycomb proteins in the epigenetic regulation of neuronal and hematopoietic stem cells: study concerning the Polycomb group proteins, regarding the neuronal stem cells' proliferation regulation.

Name and type of organisation providing education and training	Centro de Investigaciones Biológicas – Consejo Superior de Investigación Científica (CIB-CSIC) Biology laboratory of Dr. Miguel Angel Vidal Calle Ramiro de Maeztu, Madrid
Dates	2011 - 2012
Title of qualification awarded	Postgraduate training, project contract
Principal subjects/occupational skills covered	Postgraduate internship conducted at the CNIO in Madrid. The project was focused on the identification of cancer stem cells in the development of pancreatic adenocarcinoma. Centro Nacional de Investigación Oncológicas – Instituto de Salud Carlos III (CNIO-ISCIII) Laboratory of molecular oncology directed by Dr. Mariano Barbacid.
Dates	2007 - 2010
Title of qualification awarded	Master's degree in pharmaceutical biotechnology
Principal subjects/occupational skills covered	Thesis title "Evaluation of flavonoids as potential anti-tumor agents," supervisor Prof. Patrizia Hrelia, professor of Pharmacology, University of Bologna Alma Mater Studiorum - University of Bologna - Faculty of PHARMACY First Class: 110/110
Dates	03/2009-10/2009
Title of qualification awarded	LLP Student/Erasmus Program: pursuing the Master's Thesis.
Principal subjects/occupational skills covered	Internship training at the Department of Pharmacology, University of Las Palmas de Gran Canaria. Study and evaluation of the use of Flavonoids as anticancer agents. Department of Pharmacology, University of Las Palmas de Gran Canaria
Dates	2004-2007
Title of qualification awarded	Bachelor's Degree in Biotechnology
Principal subjects/occupational skills covered	Alma Mater Studiorum - University of Bologna - Faculty of Mathematical, Physical and Natural Sciences
Dates	04/2007- 09/2007
Title of qualification awarded	Curricular internship for the Bachelor's Thesis
Principal subjects/occupational skills covered	Internship aimed at studying an enzyme ubiquitin-protein ligase, RNF8, and its possible interactions with the genome guardian protein p53. Institut de Biologia Molecular de Barcelona (I.B.M.B.-CSIC). Department of Cell Biology, Institute of Molecular Biology. Barcelona, Spain.
Personal skills and competences (Biographical sketch)	
Mother tongue(s)	Italian
Other language(s)	English, Spanish

Self-assessment

European level ()*

English

Spanish

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
	B2		B2		B2		B2		B2
	C1		C1		C1		C1		C1

(*) [*Common European Framework of Reference for Languages*](#)

ORCID, Researcher ID, ORCID

ORCID: 0000-0001-6846-5435, Scopus ID: 57214796312

H-index, Total Citation Index

7

Bibliography

- Bravaccini, S., Nicolini, F., Zanoni, M., Gaimari, A., Cerchione, C., Maltoni, R., Pirini, F., Mazzotti, L., Cortesi, M., Ravaioli, S., Tumedei, M.M., Mazza, M.
Why the complications of COVID-19 patients differ in elderly and young cancer patients (2022) *Translational Oncology*, 26, art. no. 101541, .
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138595118&doi=10.1016%2fj.tranon.2022.101541&partnerID=40&md5=9511c1dbc410db652b7ac2531e415ae7>
DOI: 10.1016/j.tranon.2022.101541
- Martino, M., Naso, V., Loteta, B., Canale, F.A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., Mazza, M., Bravaccini, S., Derudas, D., Martinelli, G., Cerchione, C.
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon (2022) *International Journal of Molecular Sciences*, 23 (21), art. no. 13332, .
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141559348&doi=10.3390%2fijms232113332&partnerID=40&md5=9a83bd71cbcd1d2f44e576a1e479dd2b>
DOI: 10.3390/ijms232113332
- Tettamanti, S., Rotiroti, M.C., Giordano Attianese, G.M.P., Arcangeli, S., Zhang, R., Banerjee, P., Galletti, G., McManus, S., Mazza, M., Nicolini, F., Martinelli, G., Ivan, C., Veliz Rodriguez, T., Barbaglio, F., Scarfò, L., Ponzoni, M., Wierda, W., Gandhi, V., Keating, M., Biondi, A., Caligaris-Cappio, F., Biagi, E., Ghia, P., Bertilaccio, M.T.S.
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia (2022) *Leukemia and Lymphoma*, 63 (7), pp. 1566-1579. Cited 3 times.
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126377133&doi=10.1080%2f10428194.2022.2043299&partnerID=40&md5=748a28548a4e0c9a9be5ebc99da3a6c1>
DOI: 10.1080/10428194.2022.2043299
- Martino, M., Canale, F.A., Alati, C., Vincelli, I.D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., Nicolini, F., Di Rorà, A.G.L., Simonetti, G., Ronconi, S., Ceccolini, M., Musuraca, G., Martinelli, G., Cerchione, C.
Cart-cell therapy: Recent advances and new evidence in multiple myeloma (2021) *Cancers*, 13 (11), art. no. 2639, . Cited 10 times.
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106614249&doi=10.3390%2fcancers13112639&partnerID=40&md5=b3743bd05ae7373c56ad2b37937adc19>
DOI: 10.3390/cancers13112639
- Nicolini, F., Bravaccini, S., Mazza, M., Gruszka, A.M., Tazzari, M., Martín-Antonio, B., Juan, M., Ibrahim, T., Maltoni, R., Martinelli, G., Cerchione, C.
Car t cells targeting options in the fight against multiple myeloma (2021) *Panminerva Medica*, 63 (1), pp. 37-45. Cited 2 times.
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100880952&doi=10.23736%2fS0031-0808.20.04146-4&partnerID=40&md5=70f8045d31b587e1a463215b200d1e4c>
DOI: 10.23736/S0031-0808.20.04146-4
- Bravaccini, S., Fonzi, E., Tebaldi, M., Angeli, D., Martinelli, G., Nicolini, F., Parrella, P., Mazza, M.
Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19 (2021) *Cell Transplantation*, 30, . Cited 13 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100681445&doi=10.1177%2f0963689721991477&partnerID=40&md5=8a7cd90184812f66f0d4c9b236372587>

DOI: 10.1177/0963689721991477

Bocchini, M., Nicolini, F., Severi, S., Bongiovanni, A., Ibrahim, T., Simonetti, G., Grassi, I., Mazza, M.

Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review

(2020) *Frontiers in Oncology*, 10, art. no. 831, . Cited 18 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086517796&doi=10.3389%2ffonc.2020.00831&partnerID=40&md5=4c652c7626b120b1fcee266943ee2905>

DOI: 10.3389/fonc.2020.00831

Nicolini, F., Bocchini, M., Angeli, D., Bronte, G., Delmonte, A., Crinò, L., Mazza, M.

Fully human antibodies for malignant pleural mesothelioma targeting

(2020) *Cancers*, 12 (4), art. no. 915, . Cited 3 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083767275&doi=10.3390%2fcancers12040915&partnerID=40&md5=df90a425a8d37563be1181c64b2a3c97>

DOI: 10.3390/cancers12040915

Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., Mazza, M.

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

(2020) *Frontiers in Oncology*, 9, art. no. 1519, . Cited 42 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079113047&doi=10.3389%2ffonc.2019.01519&partnerID=40&md5=f978ec20edc14e5abce85aa725c9b7d8>

DOI: 10.3389/fonc.2019.01519

Ravaoli, S., Tebaldi, M., Fonzi, E., Angeli, D., Mazza, M., Nicolini, F., Lucchesi, A., Fanini, F., Pirini, F., Tumedei, M.M., Cerchione, C., Viale, P., Sambri, V., Martinelli, G., Bravaccini, S. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients

(2020) *Cell Transplantation*, 29, . Cited 18 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094838080&doi=10.1177%2f0963689720968749&partnerID=40&md5=3b8000c3963071493e7d91904fb5dcb5>

DOI: 10.1177/0963689720968749

Bravo, M., Nicolini, F., Starowicz, K., Barroso, S., Calés, C., Aguilera, A., Vidal, M. Polycomb RING1A- and RING1B-dependent histone H2A monoubiquitylation at pericentromeric regions promotes S-phase progression

(2015) *Journal of Cell Science*, 128 (19), pp. 3660-3671. Cited 20 times.

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946060215&doi=10.1242%2fjcs.173021&partnerID=40&md5=949fb50d39c6e8bbb7fd9d7577e900c4>

DOI: 10.1242/jcs.173021

Nicolini, F., Burmistrova, O., Marrero, M.T., Torres, F., Hernández, C., Quintana, J., Estévez, F.

Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells

(2014) Molecular Carcinogenesis, 53 (12), pp. 939-950. Cited 43 times.
<https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911420590&doi=10.1002%2fmc.22055&partnerID=40&md5=7fa7b45f2a3434dd7cf6edbe295beb23>

DOI: 10.1002/mc.22055

Date, 22/12/22

Signature *Fabio Nicolini* _____